PE20212304A1 - Inhibidores de il-17a imidazo[1,2-b]piridazin-2-il - Google Patents
Inhibidores de il-17a imidazo[1,2-b]piridazin-2-ilInfo
- Publication number
- PE20212304A1 PE20212304A1 PE2021001117A PE2021001117A PE20212304A1 PE 20212304 A1 PE20212304 A1 PE 20212304A1 PE 2021001117 A PE2021001117 A PE 2021001117A PE 2021001117 A PE2021001117 A PE 2021001117A PE 20212304 A1 PE20212304 A1 PE 20212304A1
- Authority
- PE
- Peru
- Prior art keywords
- imidazo
- inhibitors
- pyridazine
- pyridazin
- methyl
- Prior art date
Links
- 102000013691 Interleukin-17 Human genes 0.000 title abstract 2
- 108050003558 Interleukin-17 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 -CH2F Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- RJMNXENEGWKIHR-RXVVDRJESA-N 3-cyclopropyl-N-[(S)-(4,4-difluorocyclohexyl)-[7-[[(4S)-2-oxo-4-(trifluoromethyl)imidazolidin-1-yl]methyl]imidazo[1,2-b]pyridazin-2-yl]methyl]-1,2-oxazole-4-carboxamide Chemical compound C1CC1C2=NOC=C2C(=O)N[C@@H](C3CCC(CC3)(F)F)C4=CN5C(=N4)C=C(C=N5)CN6C[C@H](NC6=O)C(F)(F)F RJMNXENEGWKIHR-RXVVDRJESA-N 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
Referido a un compuesto de formula II, en donde X es CH o N; R1 es -CH3, -CH2F, -CH2CH3, entre otros; R2 es -H o -CH2OCH3; o una sal aceptable desde el punto de vista farmaceutico de este. Un compuesto seleccionado es 3-ciclopropil-N-[(S)-(4,4-difluorociclohexil)-[7-[[(4S)-2-oxo-4-(trifluorometil)imidazolidin-1-il]metil]imidazo[1,2-b]piridazin-2-il]metil]isoxazol-4-carboxamida. Estos compuestos de imidazo[1,2-b]piridazin-2-il son inhibidores de IL-17A. Tambien se refiere metodos para preparar dichos compuestos, composiciones farmaceuticas de estos y su uso en el tratamiento de la psoriasis, la artritis reumatoide y esclerosis multiple.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789247P | 2019-01-07 | 2019-01-07 | |
| US201962842770P | 2019-05-03 | 2019-05-03 | |
| PCT/US2020/012115 WO2020146194A1 (en) | 2019-01-07 | 2020-01-03 | Imidazo[1,2-b]pyridazine il-17a inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20212304A1 true PE20212304A1 (es) | 2021-12-10 |
Family
ID=69423406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001117A PE20212304A1 (es) | 2019-01-07 | 2020-01-03 | Inhibidores de il-17a imidazo[1,2-b]piridazin-2-il |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US12252491B2 (es) |
| EP (1) | EP3908585B1 (es) |
| JP (1) | JP7291226B2 (es) |
| KR (1) | KR102600451B1 (es) |
| CN (1) | CN113286795B (es) |
| AU (1) | AU2020207196B2 (es) |
| BR (1) | BR112021011095B1 (es) |
| CA (1) | CA3125788C (es) |
| CL (1) | CL2021001720A1 (es) |
| CO (1) | CO2021008776A2 (es) |
| CR (1) | CR20210357A (es) |
| DO (1) | DOP2021000132A (es) |
| EC (1) | ECSP21050201A (es) |
| ES (1) | ES2977743T3 (es) |
| IL (1) | IL284228B2 (es) |
| JO (1) | JOP20210179A1 (es) |
| MA (1) | MA54696A (es) |
| MX (1) | MX2021008176A (es) |
| NZ (1) | NZ777806A (es) |
| PE (1) | PE20212304A1 (es) |
| PH (1) | PH12021551632A1 (es) |
| SA (1) | SA521422452B1 (es) |
| SG (1) | SG11202105776WA (es) |
| TW (2) | TW202214648A (es) |
| WO (1) | WO2020146194A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019410261B2 (en) | 2018-12-19 | 2025-10-02 | Leo Pharma A/S | Amino-acid anilides as small molecule modulators of IL-17 |
| GB201909190D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| MX2022013647A (es) * | 2020-04-30 | 2023-02-01 | Janssen Pharmaceutica Nv | Imidazopiridazinas como moduladores de il-17. |
| AU2021290172A1 (en) | 2020-06-12 | 2023-02-16 | Leo Pharma A/S | Small molecule modulators of IL-17 |
| WO2021255085A1 (en) | 2020-06-18 | 2021-12-23 | Leo Pharma A/S | Small molecule modulators of il-17 |
| EP4168400A1 (en) | 2020-06-18 | 2023-04-26 | LEO Pharma A/S | Small molecule modulators of il-17 |
| WO2021255086A1 (en) | 2020-06-18 | 2021-12-23 | Leo Pharma A/S | Small molecule modulators of il-17 |
| EP3943495A1 (en) | 2020-07-24 | 2022-01-26 | Leo Pharma A/S | Small molecule modulators of il-17 |
| CN113999234B (zh) * | 2020-07-28 | 2023-03-07 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2022096412A1 (en) | 2020-11-09 | 2022-05-12 | UCB Biopharma SRL | Dicyclopropylmethyl derivatives as il-17 modulators |
| WO2022096411A1 (en) | 2020-11-09 | 2022-05-12 | UCB Biopharma SRL | Dicyclopropylmethyl derivatives as il-17 modulators |
| US20240140951A1 (en) * | 2020-12-14 | 2024-05-02 | UCB Biopharma SRL | Imidazopyridazine derivatives as il-17 modulators |
| AR126255A1 (es) | 2021-07-01 | 2023-10-04 | UCB Biopharma SRL | Derivados de imidazotriazina como moduladores de il-17 |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| MX2024003772A (es) * | 2021-09-27 | 2024-06-19 | Janssen Pharmaceutica Nv | Compuestos de imidazopiridazina inhibidores de il-17. |
| CA3233625A1 (en) * | 2021-09-27 | 2023-03-30 | Janssen Pharmaceutica Nv | Imidazopyridazine il-17 inhibitor compounds |
| WO2023078319A1 (zh) * | 2021-11-04 | 2023-05-11 | 海思科医药集团股份有限公司 | 一种可抑制il-17a的杂环化合物及其用途 |
| WO2023111181A1 (en) | 2021-12-16 | 2023-06-22 | Leo Pharma A/S | Small molecule modulators of il-17 |
| US20250197378A1 (en) | 2022-03-04 | 2025-06-19 | Leo Pharma A/S | Small molecule modulators of il-17 |
| CN114736104B (zh) * | 2022-04-20 | 2024-04-19 | 上海恩氟佳科技有限公司 | 一种二氟乙醛缩半乙醇的合成方法 |
| WO2023225664A1 (en) * | 2022-05-19 | 2023-11-23 | Dice Alpha, Inc. | Lactam substituted imidazopyridazine il-17a modulators and uses thereof |
| GB202210731D0 (en) | 2022-07-22 | 2022-09-07 | UCB Biopharma SRL | Therapeutic agents |
| WO2024115662A1 (en) | 2022-12-02 | 2024-06-06 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2024138286A1 (en) * | 2022-12-26 | 2024-07-04 | Usynova Pharmaceuticals, Ltd. | Il-17a modulators |
| WO2024163365A1 (en) * | 2023-01-30 | 2024-08-08 | Dice Alpha, Inc. | Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof |
| EP4665454A1 (en) * | 2023-02-13 | 2025-12-24 | Dice Alpha, Inc. | Imidazotriazine il-17a modulators and uses thereof |
| CN121311483A (zh) * | 2023-03-28 | 2026-01-09 | 詹森药业有限公司 | 含内酰胺的咪唑并哒嗪il-17抑制剂化合物 |
| CN121311485A (zh) * | 2023-04-11 | 2026-01-09 | 戴斯阿尔法公司 | 取代的6-咪唑并哒嗪il-17a调节剂及其用途 |
| WO2025133234A1 (en) | 2023-12-22 | 2025-06-26 | Draupnir Bio Aps | Sortilin binders and bifunctional compounds thereof |
| WO2025175249A1 (en) | 2024-02-14 | 2025-08-21 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| WO2025247285A1 (zh) * | 2024-05-28 | 2025-12-04 | 西藏海思科制药有限公司 | 一种可抑制il-17a的杂环化合物制备及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9702213D0 (en) * | 1996-02-24 | 1997-03-26 | Zeneca Ltd | Chemical compounds |
| JP2009502734A (ja) | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Ｌｃｋ阻害剤としての縮合複素環 |
| WO2007104696A1 (en) * | 2006-03-15 | 2007-09-20 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antimalarial agents having polyaromatic structure |
| SG178786A1 (en) * | 2006-11-13 | 2012-03-29 | Lilly Co Eli | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
| EP2809660B1 (en) | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| US9428511B2 (en) * | 2012-09-06 | 2016-08-30 | Bristol-Myers Squibb Company | Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
| WO2014066726A2 (en) | 2012-10-26 | 2014-05-01 | Ensemble Therapeutics Corporation | Compounds for modulating il-17 |
| UA112028C2 (uk) * | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
| CA2901527A1 (en) | 2013-02-20 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors |
| EP3080131B1 (en) * | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| US10385034B2 (en) | 2014-09-05 | 2019-08-20 | The Cleveland Clinic Foundation | Flavonoid IL-17A inhibitors |
| AU2016326704B2 (en) | 2015-09-23 | 2021-01-28 | Reata Pharmaceuticals, Inc. | C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses |
| JP6843135B2 (ja) * | 2015-11-18 | 2021-03-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 |
| GB201709456D0 (en) | 2017-06-14 | 2017-07-26 | Ucb Biopharma Sprl | Therapeutic agents |
| ES2963417T3 (es) | 2018-01-15 | 2024-03-27 | UCB Biopharma SRL | Derivados de imidazol condensados como moduladores de IL-17 |
| CN110511213B (zh) | 2018-05-22 | 2021-10-19 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| AU2019410261B2 (en) | 2018-12-19 | 2025-10-02 | Leo Pharma A/S | Amino-acid anilides as small molecule modulators of IL-17 |
| TWI839461B (zh) | 2019-02-06 | 2024-04-21 | 美商戴斯阿爾法股份有限公司 | Il-17a調節物及其用途 |
-
2020
- 2020-01-02 TW TW111100669A patent/TW202214648A/zh unknown
- 2020-01-02 TW TW109100073A patent/TWI752400B/zh not_active IP Right Cessation
- 2020-01-03 BR BR112021011095-0A patent/BR112021011095B1/pt active IP Right Grant
- 2020-01-03 US US17/419,997 patent/US12252491B2/en active Active
- 2020-01-03 WO PCT/US2020/012115 patent/WO2020146194A1/en not_active Ceased
- 2020-01-03 EP EP20703322.6A patent/EP3908585B1/en active Active
- 2020-01-03 AU AU2020207196A patent/AU2020207196B2/en active Active
- 2020-01-03 JO JOP/2021/0179A patent/JOP20210179A1/ar unknown
- 2020-01-03 SG SG11202105776WA patent/SG11202105776WA/en unknown
- 2020-01-03 KR KR1020217020765A patent/KR102600451B1/ko active Active
- 2020-01-03 ES ES20703322T patent/ES2977743T3/es active Active
- 2020-01-03 CR CR20210357A patent/CR20210357A/es unknown
- 2020-01-03 CA CA3125788A patent/CA3125788C/en active Active
- 2020-01-03 IL IL284228A patent/IL284228B2/en unknown
- 2020-01-03 PH PH1/2021/551632A patent/PH12021551632A1/en unknown
- 2020-01-03 NZ NZ777806A patent/NZ777806A/en unknown
- 2020-01-03 CN CN202080008309.9A patent/CN113286795B/zh active Active
- 2020-01-03 MX MX2021008176A patent/MX2021008176A/es unknown
- 2020-01-03 MA MA054696A patent/MA54696A/fr unknown
- 2020-01-03 PE PE2021001117A patent/PE20212304A1/es unknown
- 2020-01-03 JP JP2021539549A patent/JP7291226B2/ja active Active
-
2021
- 2021-06-22 DO DO2021000132A patent/DOP2021000132A/es unknown
- 2021-06-25 CL CL2021001720A patent/CL2021001720A1/es unknown
- 2021-07-01 CO CONC2021/0008776A patent/CO2021008776A2/es unknown
- 2021-07-01 SA SA521422452A patent/SA521422452B1/ar unknown
- 2021-07-07 EC ECSENADI202150201A patent/ECSP21050201A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20212304A1 (es) | Inhibidores de il-17a imidazo[1,2-b]piridazin-2-il | |
| PE20241127A1 (es) | Compuestos triciclicos como inhibidores de kras | |
| RU2336275C2 (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция | |
| ECSP22050936A (es) | Compuestos tric?clicos sustituidos | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| CO2025010435A2 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20081888A1 (es) | ANALOGOS DE PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE CINASA mTOR Y CINASA PI3 | |
| PE20050361A1 (es) | Compuesto de anillo fusionado conteniendo nitrogeno referido a la inhibicion de integrasa vih | |
| PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
| PE20030010A1 (es) | Triazolopiridinas como inhibidores de quinasas | |
| PE20020381A1 (es) | COMPUESTOS DE PIRROLO[2,3-d]PIRIMIDINA COMO INHIBIDORES DE LA PROTEINA QUINASA | |
| PE20091556A1 (es) | Derivado heterociclico fusionado y su uso | |
| AR086254A1 (es) | Derivados de imidazol utiles para el tratamiento de artritis | |
| PE20020274A1 (es) | Compuestos de biciclo-pirazoles como inhibidores de quinasas, procedimiento para su preparacion a composiciones farmaceuticas que los comprenden | |
| MX9303441A (es) | Procedimiento para la preparacion de acido clavulanico. | |
| PE20200665A1 (es) | Compuestos espirociclicos y sus metodos de preparacion y uso | |
| PE20121276A1 (es) | Compuestos espirociclicos que contienen nitrogeno y su uso medicinal | |
| AR117177A1 (es) | DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa | |
| PE20080931A1 (es) | Imidazopirazinas como inhibidores de proteina quinasa | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
| CL2021002621A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| MX2020008570A (es) | Inhibidores de arginasa y sus metodos de uso. | |
| PE20210404A1 (es) | Derivados de pirrolo [1,2-b] piridazina | |
| RU2017117559A (ru) | Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение |